Accueil
Marchés
Graphique & Idées
Algo
Nouvelles
Store
Courtiers
Télécharger
Calendrier Economique
Signaux de trading
Terminal Web
Heatmap
Tapez
/
pour rechercher : @user, $symbol
Recherche
Se connecter
Créer un compte
Français
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Italiano
Türkçe
IMCR
#2129
Immunocore Holdings plc American Depositary Shares
31.690
0
USD
+0.70%
Secteur:
Soins de Santé
Base:
USD
Devise de Profit:
USD
Range quotidien
Range Annuel
Changement quotidien
+0.70%
Changement Mensuel
+4.38%
Evolution sur 6 mois
-5.35%
Changement Annuel
-5.35%
Clôture Précédente
31.470
0
Open
31.690
0
Bid
Ask
Low
31.690
0
High
31.690
0
Volume
87
Marchés
Actions des Marchés US
Soins de Santé
IMCR
Open full chart
Financials
Overview
Relevé
Statistics
Quarterly
Annual
Income statement
Balance sheet
Cash flow
Value
2020
2021
2022
2023
2024
2025
Total assets
—
—
—
597 M
1.01 B
1.07 B
Total liabilities
—
—
—
228.16 M
648.79 M
686.24 M
Total equity
—
—
—
368.84 M
360.72 M
381.03 M
Total liabilities & shareholders' equities
—
—
—
597 M
1.01 B
1.07 B
Total debt
—
—
—
48.01 M
391.01 M
393.13 M
Net debt
—
—
—
-394.62 M
-429.36 M
-471.03 M
Immunocore Holdings plc - American Depositary Shares
Immunocore is a global commercial-stage biotechnology company, based in Oxfordshire, which researches and develops biological drugs using soluble T-cell receptor technology.
Nouvelles
Ideaya Biosciences Surges On Promising Results For Hard-To-Treat Melanoma
Jefferies maintient sa recommandation Conserver sur Immunocore face aux données d’un concurrent
Jefferies abaisse la note d’Immunocore sur fond d’inquiétudes liées aux revenus
Jefferies downgrades Immunocore stock rating on revenue concerns
Immunocore à la conférence Leerink : croissance stratégique et innovation
Immunocore at Leerink Conference: Strategic Growth and Innovation
Immunocore Holdings plc 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:IMCR) 2026-02-25
Immunocore Holdings plc (IMCR) Q4 2025 Earnings Call Transcript
Le BPA de Immunocore Holdings a manqué les attentes de 0,40$, le CA en dessous des prévisions
Immunocore Holdings earnings missed by $0.40, revenue fell short of estimates
JAZZ Stock Rises as Q4 Earnings & Sales Top Expectations
RXRX Q4 Loss Narrower Than Expected, Revenues Increase Y/Y, Stock Up